Department of Respiratory Medicine, Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Hans Bornefalk AB, Vallentuna, Sweden.
BMJ Open Respir Res. 2019 Sep 18;6(1):e000418. doi: 10.1136/bmjresp-2019-000418. eCollection 2019.
Breathlessness is the cardinal symptom in both cardiac and respiratory diseases, and includes multiple dimensions. The multidimensional instrument Dyspnoea-12 has been developed to assess both physical and affective components of breathlessness. This study aimed to perform a clinical validation of the Swedish version of Dyspnoea-12 in outpatients with cardiorespiratory disease.
Stable outpatients with cardiorespiratory disease and self-reported breathlessness in daily life were recruited from five Swedish centres. Assessments of Dyspnoea-12 were performed at baseline, after 30-90 min and after 2 weeks. Factor structure was tested using confirmatory factor analysis and internal consistency using Cronbach's alpha. Test-retest reliability was analysed using intraclass correlation coefficients (ICCs). Concurrent validity at baseline was evaluated by examining correlations with lung function and several instruments for the assessment of symptoms and health status.
In total, 182 patients were included: with the mean age of 69 years and 53% women. The main causes of breathlessness were chronic obstructive pulmonary disease (COPD; 25%), asthma (21%), heart failure (19%) and idiopathic pulmonary fibrosis (19%). Factor analysis confirmed the expected underlying two-component structure with two subdomains. The Dyspnoea-12 total score, physical subdomain score and affective subdomain scores showed high internal consistency (Cronbach's alpha 0.94, 0.84 and 0.80, respectively) and acceptable reliability after 2 weeks (ICC total scores 0.81, 0.79 and 0.73). Dyspnoea-12 showed concurrent validity with the instruments modified Medical Research Council scale, COPD Assessment Test, European Quality of Life-Five Dimensions-Five levels, the Functional Assessment of Chronic Illness Therapy-Fatigue, the Hospital Anxiety and Depression Scale, and with forced expiratory volume in 1 s in percentage of predicted value. The results were consistent across different cardiorespiratory conditions.
The Dyspnoea-12 is a valid instrument for multidimensional assessment of breathlessness in Swedish patients with cardiorespiratory diseases.
呼吸困难是心脏和呼吸系统疾病的主要症状,包括多个维度。多维工具 Dyspnoea-12 旨在评估呼吸困难的身体和情感成分。本研究旨在对瑞典版 Dyspnoea-12 在患有心肺疾病的门诊患者中进行临床验证。
从瑞典的五个中心招募了患有心肺疾病且在日常生活中自述呼吸困难的稳定门诊患者。在基线时、30-90 分钟后和 2 周后进行 Dyspnoea-12 评估。使用验证性因子分析测试因子结构,使用 Cronbach's alpha 测试内部一致性。使用组内相关系数 (ICC) 分析测试-重测可靠性。在基线时评估同时效度,方法是检查与肺功能和用于评估症状和健康状况的几种工具的相关性。
共纳入 182 例患者:平均年龄 69 岁,53%为女性。呼吸困难的主要原因是慢性阻塞性肺疾病 (COPD; 25%)、哮喘 (21%)、心力衰竭 (19%) 和特发性肺纤维化 (19%)。因子分析证实了预期的双成分结构,具有两个亚域。Dyspnoea-12 总分、身体亚域得分和情感亚域得分显示出较高的内部一致性(Cronbach's alpha 分别为 0.94、0.84 和 0.80),且 2 周后可靠性可接受(ICC 总分分别为 0.81、0.79 和 0.73)。Dyspnoea-12 与改良的医学研究委员会量表、COPD 评估测试、欧洲生活质量-五维度-五个等级、慢性疾病治疗的功能评估-疲劳、医院焦虑和抑郁量表以及用力呼气量在预测值中的百分比具有同时效度。结果在不同的心肺疾病情况下一致。
Dyspnoea-12 是一种用于评估瑞典心肺疾病患者呼吸困难的多维工具。